Literature DB >> 17314275

Nuclear localization of the parafibromin tumor suppressor protein implicated in the hyperparathyroidism-jaw tumor syndrome enhances its proapoptotic function.

Ling Lin1, Meggan Czapiga, Lylia Nini, Jian-Hua Zhang, William F Simonds.   

Abstract

Parafibromin is a tumor suppressor protein encoded by HRPT2, a gene recently implicated in the hereditary hyperparathyroidism-jaw tumor syndrome, parathyroid cancer, and a subset of kindreds with familial isolated hyperparathyroidism. Human parafibromin binds to RNA polymerase II as part of a PAF1 transcriptional regulatory complex. The mechanism by which loss of parafibromin function can lead to neoplastic transformation is poorly understood. Because the subcellular localization of parafibromin is likely to be critical for its function with the nuclear PAF1 complex, we sought to experimentally define the nuclear localization signal (NLS) of parafibromin and examine its potential role in parafibromin function. Using site-directed mutagenesis, we define a dominant bipartite NLS and a secondary NLS, both in the NH(2)-terminal region of parafibromin whose combined mutation nearly abolishes nuclear targeting. The NLS-mutant parafibromin is significantly impaired in its association with endogenous Paf1 and Leo1. We further report that overexpression of wild-type but not NLS-mutant parafibromin induces apoptosis in transfected cells. Inhibition of endogenous parafibromin expression by RNA interference inhibits the basal rate of apoptosis and apoptosis resulting from DNA damage induced by camptothecin, a topoisomerase I inhibitor. These experiments identify for the first time a proapoptotic activity of endogenous parafibromin likely to be important in its role as a tumor suppressor and show a functional role for the NLS of parafibromin in this activity.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17314275     DOI: 10.1158/1541-7786.MCR-06-0129

Source DB:  PubMed          Journal:  Mol Cancer Res        ISSN: 1541-7786            Impact factor:   5.852


  25 in total

1.  Cytoplasmic polyadenylation element binding protein is a conserved target of tumor suppressor HRPT2/CDC73.

Authors:  J-H Zhang; L M Panicker; E M Seigneur; L Lin; C D House; W Morgan; W C Chen; H Mehta; M Haj-Ali; Z-X Yu; W F Simonds
Journal:  Cell Death Differ       Date:  2010-03-26       Impact factor: 15.828

Review 2.  Clinical and molecular genetics of parathyroid neoplasms.

Authors:  John M Sharretts; William F Simonds
Journal:  Best Pract Res Clin Endocrinol Metab       Date:  2010-06       Impact factor: 4.690

3.  The clinicopathological significances and biological functions of parafibromin expression in head and neck squamous cell carcinomas.

Authors:  Zhuo Zhang; Xue-Feng Yang; Ke-Qiang Huang; Li Ren; Wen-Feng Gou; Dao-Fu Shen; Shuang Zhao; Hong-Zhi Sun; Yasuo Takano; Hua-Chuan Zheng
Journal:  Tumour Biol       Date:  2015-07-01

4.  Defective nucleolar localization and dominant interfering properties of a parafibromin L95P missense mutant causing the hyperparathyroidism-jaw tumor syndrome.

Authors:  Leelamma M Panicker; Jian-Hua Zhang; Pradeep K Dagur; Matthew J Gastinger; William F Simonds
Journal:  Endocr Relat Cancer       Date:  2010-05-18       Impact factor: 5.678

5.  The PAF1 complex differentially regulates cardiomyocyte specification.

Authors:  Adam D Langenbacher; Catherine T Nguyen; Ann M Cavanaugh; Jie Huang; Fei Lu; Jau-Nian Chen
Journal:  Dev Biol       Date:  2011-02-19       Impact factor: 3.582

Review 6.  Parathyroid carcinoma.

Authors:  B Givi; J P Shah
Journal:  Clin Oncol (R Coll Radiol)       Date:  2010-05-26       Impact factor: 4.126

7.  The parafibromin tumor suppressor protein inhibits cell proliferation by repression of the c-myc proto-oncogene.

Authors:  Ling Lin; Jian-Hua Zhang; Leelamma M Panicker; William F Simonds
Journal:  Proc Natl Acad Sci U S A       Date:  2008-11-05       Impact factor: 11.205

8.  The roles of parafibromin expression in ovarian epithelial carcinomas: a marker for differentiation and prognosis and a target for gene therapy.

Authors:  Dao-Fu Shen; Xin Liu; Xue-Feng Yang; Lei Fang; Yang Gao; Shuang Zhao; Ji-Cheng Wu; Shuai Shi; Jun-Jun Li; Xiang-Xuan Zhao; Wen-Feng Gou; Hua-Chuan Zheng
Journal:  Tumour Biol       Date:  2015-09-26

Review 9.  Update on parathyroid carcinoma.

Authors:  F Cetani; E Pardi; C Marcocci
Journal:  J Endocrinol Invest       Date:  2016-03-21       Impact factor: 4.256

10.  A Young Male with Parafibromin-Deficient Parathyroid Carcinoma Due to a Rare Germline HRPT2/CDC73 Mutation.

Authors:  Alisha Kapur; Narendra Singh; Ozgur Mete; Robert A Hegele; I George Fantus
Journal:  Endocr Pathol       Date:  2018-12       Impact factor: 3.943

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.